-
Dave Mulder- Managing DirectorOpen or Close
With more than 25 years of experience in financial management, turnaround / restructuring, mergers & acquisitions, and dispositions advisory services, Dave re-launched Mulder Associates in 2014.
From 2012 to 2014, Dave was a Managing Director in the Transaction Advisory Group at Alvarez & Marsal, where he provided interim corporate development and financial and operating due diligence services. Services offerings crossed every phase of a transaction from sourcing through integration on both the buy-side and sell-side.
In 2007, Dave launched Mulder Associates, Inc. and for the next five years served as an interim Chief Financial Officer and interim Corporate Development Officer. In addition, he led dozens of acquisitions for clients in the business services, consumer electronics, equipment leasing, correctional services, health care, pharmaceutical / biotech, and financial industries. He also has participated in raising capital for companies and has provided financial management, operational reviews, and strategic planning for clients in the equipment leasing, pharmaceutical services, and other industries.
From 2004 to 2007, Dave invested more than $7 billion as the Senior Vice President of Corporate Development at Mylan Labs (a NYSE traded company) and Mayne Pharma (an Australian exchange traded company), where he led the global acquisition of enterprises and products. Dave was a member of operating committees of both companies overseeing operations in 24 countries and led the strategic planning process, bringing these companies into new markets and therapeutic areas.
From 2001 to 2004, Dave served in various interim CEO, CFO, and Board of Director advisory roles for GE Equity portfolio companies. During this time, Dave specialized in crisis management for seven companies across multiple industries, including software, media, manufacturing, and Internet based businesses, making unprofitable ventures profitable, selling distressed companies, and liquidating nonperforming assets.
In 2000, Dave joined Cigna Corporation as the Senior Vice President of New Business Development to develop global growth strategies and execute international acquisitions, primarily for Cigna International. He left Cigna Corporation in 2001 to work exclusively on troubled portfolio companies owned by GE Equity.
From 1995 to 2000, Dave was a Senior Vice President of Corporate and Business Development for a multibillion dollar GE Capital subsidiary. Prior to that he was a Managing Director in GE Capital's Executive Vice President's Office, which managed more than $300 billion in assets for eight GE Capital subsidiaries. During these five years, Dave invested approximately $2 billion by acquiring companies for GE Capital in multiple industries throughout the world including the equipment rental, commercial banking, credit card, and computer industries. He also worked with GE Capital Ventures, which later was merged into GE Equity, investing in small enterprise companies.
Dave began his career at Arthur Andersen in the New York Office's Audit and Business Advisory Group where he was a certified public accountant. He later joined Arthur Andersen's Corporate Finance Consulting Practice, where he held various positions, the last of which was Senior Manager. During his 12 years at Arthur Andersen, Dave specialized in financial and operational due diligence, valuation, initial public offerings, and audit related services for clients in multiple industries including manufacturing, financial services, private equity, and professional services.
Dave received his MBA from Drexel University and his BS in Accounting from Rider University. He is a licensed CPA in New Jersey and New York. Dave has held several Board of Director positions at GE Equity portfolio companies and is an advisor to several entrepreneurs of closely held businesses.
-
Mike Mulder- Managing DirectorOpen or Close
With more than 25 years of experience in financial services, corporate development services, risk management and engineering, Mike re-launched Mulder Associates in 2014.
From 2012 to 2014, Mike was a Senior Director in the Transaction Advisory Group at Alvarez & Marsal, where he provided interim corporate development and financial and operating due diligence services. Service offerings crossed every phase of a transaction from sourcing through integration on both the buy-side and sell-side.
In 2007, Mike joined Mulder Associates, Inc. During the next 5 years, Mike led and participated in acquisitions for clients in the biotech, consumer electronics, correctional services, equipment leasing, and business services industries. He also participated in start-up ventures and provided interim management services for clients in the biotech, equipment leasing, and other industries. His services included strategic analysis and planning, operational reviews and analysis, valuations, financial forecasting, and due diligence.
From 1995 to 2007, Mike held various positions of increasing responsibility at American Express in the Risk, Information Management, and Banking division. Most recently, he served as Vice President of Credit Risk Management and Vice President of Fraud Risk Management, with responsibility over the receivables quality of the consumer charge card and lending portfolios. Mike lead cross functional teams in both the U.S. and the International markets, overseeing the development of the strategies, policies and processes that managed the credit card division's credit and fraud losses. His focus was on continual process improvement that enhanced the customer experience while reducing credit and fraud losses.
Mike started his career as an electrical engineer at Rexroth Corporation. During his seven years with the company, Mike designed customized control systems for a wide variety of industrial applications across many industries including automotive, industrial products, consumer products, steel, aluminum, and aerospace. Representative clients included General Motors, Ford, U.S. Steel, John Deere and Boeing.
Mike received his MBA from Columbia University and his BS in Electrical Engineering from Lehigh University.
-
Tim Hillman- AdvisorOpen or Close
Tim is a pharmaceutical and biotech industry advisor with Mulder Associates, Inc. and has more than 20 years of experience in business development, strategic planning, finance and research and development. Since joining Mulder Associates, Inc., clients have included Ascalon International (an oncology startup), Impax labs, JHP Pharma, Strides, and Mylan Corporation.
Since 2010, Tim has been the Vice President of Operations of Coronado Biosciences, a NASDAQ-listed biopharmaceutical company focused on novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Tim is responsible for the overall project management of CNDO-201, T. suis ova for the treatment of Crohn's Disease, MS and other autoimmune disorders, and CNDO-109, a patient-specific cell therapy for the treatment of high-risk Acute Myeloid Leukemia (AML) and other cancers. Tim has also supported corporate financing activities including public offerings with gross proceeds of more than $100 million, and a Series C financing and public listing through a Form 10 registration statement which lead to subsequent trading on NASDAQ.
From 2007 to 2010, Tim was Senior Director, Strategic Planning and Business Development for Gentium S.p.A., a NASDAQ-listed Italian biotech company developing defibrotide for the treatment and prevention of AML and other cancers. Tim led Gentium's commercial initiatives including the launch of a Named-Patient Program outside of the U.S. through Idis Limited, and a Cost Recovery program in the U.S. through US Oncology Research. Tim also led the European regulatory strategy, in which a previous formulation of defibrotide was withdrawn and re-launched (on a pre-approval basis only) with new pricing levels and a new target indication.
From 2004 to 2007, Tim was Director, Corporate Development at Mylan and Mayne Pharma (now Hospira), where he focused on product and company acquisitions. Tim also lead several in-licensing projects, including a first-to-file generic dermatology product from Dow Pharmaceutical Sciences.
From 1999 to 2004, Tim held various positions at Johnson & Johnson in sales and marketing and business development. From 1996 to 1998, Tim was a Senior Research Assistant for the University of Texas Health Science Center at San Antonio.
Tim received his MBA from Cornell University, his MS in Biochemistry from Rice University, and his BS in Biochemistry from the University of Texas, Austin.
-
Pierre Casanova - AdvisorOpen or Close
Pierre is a European advisor with Mulder Associates, Inc. and has more than 20 years of international experience in corporate and business development, strategic planning, financial management, venture capital, and mergers and acquisitions.
In 2005, Pierre founded DDH-Partners, an investment banking boutique located in Marseille, France. DDH-Partners focuses on providing expertise and management of transactions primarily for clients in the information technology, life sciences and telecommunications industries. Pierre has also served in an interim business development and integration leadership role for Mayne Pharma (U.S.), in which capacity he participated in several transactions prior to the company being acquired by a competitor.
Pierre is a board member of Ekkyo, a medical laser company, and Carewave Shielding Technologies, a breakthrough provider of solutions for electromagnetic protection. He also works closely with various regional institutional organizations such as Marseille-Innovation, the major local incubator where he provides financial strategy expertise, and PopSud, the Optics-Photonics Cluster of the region, where he helps in strategizing about future development initiatives.
From 1995 to 2005, Pierre held various executive leadership positions at General Electric Capital in the U.S. He was a Vice President at GE Equity, where he was in charge of leading investments in the media and technology industries. While at GE Equity, Pierre managed a portfolio of 40 early-stage private equity investments valued at more than $250MM, and was on the board of several U.S.- based companies. Prior to his work at GE Equity, Pierre was a Director of GE Capital Mergers and Acquisitions Group, where he led strategic cross-border transactions in various industries and successfully acquired companies in France, Germany, the United Kingdom, and the U.S.
Pierre is an adjunct professor and teaches Mergers and Acquisitions, Venture Capital, Innovation Management, and Global Strategy graduate business courses at the IAE Aix-en-Provence School of Management, University of Aix-Marseille, France.
Pierre received his MBA from New York University, his MS in Business Management from the IAE Aix-en-Provence School of Management, University of Aix-Marseille, France, and his BS degree in Physics from the University of Sussex, UK.
-
Chun Garbit - AdvisorOpen or Close
Chun is a European and Asian advisor with Mulder Associates, Inc. with more than 15 years of international experience in corporate and business development, strategic planning, and financial management.
Chun is a Partner at DDH-Partners. She joined the firm in 2006, and has led cross border business development projects for consumer goods, life sciences, engineering science (air purification, optic and photonic, semi-conductor-focused IP design) and technology based start-ups. She also specializes in working with clients on developing and executing their strategies for entering the Chinese marketplace. In addition, Chun provides financial consulting, strategic planning, operational and financial due diligence services, as well fund raising solutions to clients located in France and China.
Chun is a member of the Taiwanese Venture Capital Association (TVCA). She is also one of the co-founders and board members of Carewave Shielding Technologies.
Prior to joining DDH-Partners, Chun served as business development director of CPECF, a Marseille-headquartered consultancy group providing accountancy, tax and consulting services to small and medium sized private companies and publicly traded corporations.
Prior to her work at CPECF, Chun developed Créations Artistiques, an Aix-en-Provence-based firm that specialized in professional cosmetic retail and make-up artist training. Prior to this position, she worked for Saatchi & Saatchi in Taiwan.
Chun is a lecturer at the IAE Aix-en-Provence School of Management, University of Aix-Marseille, France. She lectures on strategy and post- merger and acquisition integration.
Chun received her MBA and her MS in International Finance from the IAE Aix-en-Provence School of Management, University of Aix-Marseille, France, and her BS in Business Administration from Hsing-Wu College of Commerce in Taipei, Taiwan.
Chun is a citizen of both France and Taiwan.